Jul 21, 2021 10:34 JST

Source: Eisai

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021

TOKYO, Jul 21, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021.

Major presentations regarding lecanemab include oral presentations about the preliminary assessment of the clinical effect of lecanemab following 18 months of treatment in the open-label extension of the Phase 2b proof of concept study (201 study) in subjects with early Alzheimer's disease (AD) and preliminary screening and baseline characteristics of the Phase 3 clinical study, AHEAD 3-45, for preclinical AD will be given. In addition, an oral presentation regarding the design of the clinical study for the investigational MTBR targeted anti-tau antibody E2814, which has been selected by the Dominantly Inherited Alzheimer Network Trials Unit "DIAN-TU" as the first investigational medicine among anti-tau drugs for the DIAN-TU tau study, will be given. A poster presentation will also be given on the results of an in vivo study of E2511, Eisai's in-house discovered and developed investigational novel oral synapse regenerant. A Phase 1 study for E2511 is underway.

Additionally, Eisai and Biogen Inc. (Nasdaq: BIIB) will hold a virtual symposium, "Defining the next-generation clinical care pathway for Alzheimer's disease: biological, technological, and healthcare perspectives," focusing on the AD treatment landscape. As the possibilities for treatment development increase, it is critical to transform the AD patient journey from a symptoms-based approach to a clinical care pathway that is guided by next-generation biomarkers and enabled with technology. Rhoda Au, Ph.D, MBA; Jeffrey Cummings, M.D, D.Sc; Soeren Mattke, M.D, D.Sc; and Wiesje van der Flier, Ph.D; four esteemed AD researchers, will review the latest advances and challenges in the integration of biomarkers and emerging digital tools into the larger healthcare ecosystem for AD.

Eisai serves as the lead in the co-development of lecanemab, an anti-Aβ protofibril antibody, which is being jointly developed by Eisai and Biogen.

Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment
July 29 2021 16:34 JST
 
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
July 27 2021 08:00 JST
 
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
July 23 2021 08:17 JST
 
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
July 19 2021 08:03 JST
 
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
July 01 2021 10:43 JST
 
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
June 24 2021 11:00 JST
 
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma
June 23 2021 14:20 JST
 
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
June 18 2021 14:02 JST
 
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
June 15 2021 08:00 JST
 
Eisai Receives Special Prize at Platinum Career Award 2021
June 09 2021 12:44 JST
 
More Press release >>

Latest Press Release


More Latest Release >>